Ruth Howells
Senior Director, Health Technology Assessment
Ruth is Head of Health Technology Assessment (HTA) at Clarivate. Ruth has overall responsibility for our Global HTA services and has been extensively involved in the development and strategic direction of HTAs, contributing in-depth knowledge of procedural processes.
Ruth oversees our global HTA services from early scientific advice, through local submissions and global HTA programs to post-submission support. With extensive experience of managing HTA submissions globally, Ruth works closely with our clients and in-house team, advising manufacturers on their role and requirements, and significantly contributes to the development and communication of the HTA strategy and evidence generation planning from an early stage.
Prior to joining Clarivate, Ruth worked for the National Institute for Health and Care Excellence (NICE) and has over 20 years’ experience in health outcomes research. Ruth has an MSc in Health Economics from the University of York and her experience in health outcomes research covers a wide range of therapeutic areas including, oncology (cervical cancer, head and neck cancer, colorectal cancer, breast cancer), respiratory disease, cardiology, nephrology, gynecology, gastroenterology and dermatology. Ruth is an expert in HTA for rare diseases and in innovative therapies such as cell and gene therapies.
Latest news
Clarivate Pulse of the Library 2026 Report Reveals AI Adoption Gaps Across Geographies, Mainland China Advancing Fastest
Organizational readiness, regional differences and evolving priorities are shaping the landscape of AI adoption in libraries London, U.K. September 9, 2026 – Clarivate Plc (NYSE:CLVT), a leading global provider of…
ShanghaiRanking’s Academic Ranking of World Universities 2026 Press Release
The 2026 Academic Ranking of World Universities (ARWU) is released today by ShanghaiRanking Consultancy. Since 2003, ARWU has been presenting the world’s top universities annually based on transparent methodology and…
